Abbott’s Panbio Rapid Antigen Test Receives CE Mark for Mass COVID-19 Screening
Shots: The approval is based on P-II CITN-09/KEYNOTE-017 study assessing Keytruda in 50 patients with recurrent LA or mMCC who had not received prior systemic therapy P-II CITN-09/KEYNOTE-017 study results: ORR 56%; CR 24%; PR 32%; DOR @6 mos./ 12 mos. (96%, 54%); median duration of exposure 6.6 mos. Keytruda (pembrolizumab) 100mg IV is a […]Read More
